financetom
Business
financetom
/
Business
/
Ecopetrol Q4 Net Income, Revenue Decline
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ecopetrol Q4 Net Income, Revenue Decline
Mar 4, 2025 3:02 PM

05:36 PM EST, 03/04/2025 (MT Newswires) -- Colombia's Ecopetrol ( EC ) reported Q4 net income of 3.898 trillion pesos ($955.9 million), down from 4.228 trillion pesos a year earlier.

One analyst polled by FactSet expected 3.134 trillion pesos.

Revenue for the quarter that ended Dec. 31 was 34.792 trillion pesos, down from 34.794 trillion pesos a year earlier.

Analysts surveyed by FactSet expected 34.081 trillion pesos.

Shares of Ecopetrol ( EC ) traded 1.9% higher in after-hours activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Nvidia Short Sellers Amass $6.6 Billion in Profits Amid Frenzy Over DeepSeek
Market Chatter: Nvidia Short Sellers Amass $6.6 Billion in Profits Amid Frenzy Over DeepSeek
Jan 28, 2025
03:06 PM EST, 01/28/2025 (MT Newswires) -- Bets against Nvidia ( NVDA ) amid a surge in interest for Chinese artificial intelligence app DeepSeek yielded one-day gains of about $6.6 billion for short sellers, Reuters reported Tuesday, citing data analytics firm Ortex. Short positions in Broadcom ( AVGO ) resulted in more than $2 billion in profits, the report added....
US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression
US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression
Jan 28, 2025
Jan 28 (Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its blockbuster drug Ozempic to lower the risk of progression of chronic kidney disease and the organ's failure, and death due to heart problems in adults with type 2 diabetes. Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same...
BRIEF-QMSK Technology Co Ltd Files For U.S. IPO - SEC FILING
BRIEF-QMSK Technology Co Ltd Files For U.S. IPO - SEC FILING
Jan 28, 2025
Jan 28 (Reuters) - QMSK Technology Co Ltd: * QMSK TECHNOLOGY CO LTD: FILES FOR U.S. IPO * QMSK TECHNOLOGY CO., LTD: EXPECT IPO OFFERING PRICE FOR ORDINARY SHARES WILL BE IN RANGE OF $4.00 TO $6.00 PER SHARE * QMSK TECHNOLOGY CO: EXPECT US IPO PRICE FOR ORDINARY SHARES WILL BE IN RANGE OF $4.00 TO $6.00 PER SHARE...
Tower Semiconductor Analyst Sees 'Attractive' Buying Opportunity Following DeepSeek Selloff
Tower Semiconductor Analyst Sees 'Attractive' Buying Opportunity Following DeepSeek Selloff
Jan 28, 2025
Benchmark analyst Cody Acree named Tower Semiconductor ( TSEM ) Inc. among recommended oversold names following Monday’s market rout, which was triggered by DeepSeek’s announcement of its advanced language model. Monday’s Selloff: Chinese AI lab DeepSeek unveiled a new large language model reportedly meeting or exceeding leading competitors’ performance at a fraction of the cost. The claims, though met with...
Copyright 2023-2025 - www.financetom.com All Rights Reserved